Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

• Published in: Clinical cancer research 2011-12, Vol.17 (24), p.7808-7815
• Main Authors: TANIGUCHI, Kazuya, UCHIDA, Junji, NISHINO, Kazumi, KUMAGAI, Toru, OKUYAMA, Takako, OKAMI, Jiro, HIGASHIYAMA, Masahiko, KODAMA, Ken, IMAMURA, Fumio, KATO, Kikuya
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - blood; Adenocarcinoma - diagnosis; Adenocarcinoma - genetics; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic agents; Biological and medical sciences; DNA Mutational Analysis - methods; DNA, Neoplasm - blood; DNA, Neoplasm - genetics; Female; Gene Frequency; Humans; Lung Neoplasms - blood; Lung Neoplasms - diagnosis; Lung Neoplasms - genetics; Male; Medical sciences; Middle Aged; Mutation; Pharmacology. Drug treatments; Pneumology; Receptor, Epidermal Growth Factor - genetics; Reproducibility of Results; Sensitivity and Specificity; Tumors of the respiratory system and mediastinum; Young Adult
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.ccr-11-1712

Examination of somatic epidermal growth factor receptor (EGFR) mutations is now a diagnostic routine for treatment of cancer using EGFR tyrosine kinase inhibitors (EGFR-TKI). Circulating tumor DNA is a promising target for noninvasive diagnostics. We evaluated its utility by quantitatively detecting activating and resistant mutations, which were measured with BEAMing (beads, emulsion, amplification, and magnetics). Twenty-three patients with lung cancer with progressive disease after EGFR-TKI treatment and 21 patients who had never been treated with EGFR-TKIs were studied. Their primary tumors were confirmed to have activating mutations. In the plasma DNA of each patient, the activating mutation found in the corresponding primary tumor and the T790M resistance mutation were quantified by BEAMing. In 32 of 44 patients, activating mutations were detected in the plasma DNA [72.7%; 95% confidence interval (CI), 58.0%-83.6%]. The T790M mutation was detected in 10 of 23 patients in the first group (43.5%; 95% CI, 25.6%-53.4%). The ratio of T790M to activating mutations ranged from 13.3% to 94.0%. The peak of the distribution of the mutation allele fraction in the plasma DNA was in the 0.1% to 1% range. The major advantage of BEAMing is its ability to calculate the fraction of T790M-positive alleles from the alleles with activating mutations. This feature enables the detection of increases and decreases in the number of T790M mutations in cancer cells, regardless of normal cell DNA contamination, which may be useful for monitoring disease progression. Circulating tumor DNA could potentially be used as an alternative method for EGFR mutation detection.